After beginning clinical trials in May, Gaithersburg, Maryland-based Novavax has moved its COVID-19 vaccine candidate into phase three of testing.

The clinical-stage biotech company that develops vaccines to prevent serious infectious diseases gained hundreds of millions of dollars to advance its vaccine candidate this year. Back in May, Novavax conducted phase one and two clinical trials of its coronavirus vaccine on 130 healthy participants ages 18 to 59 in Australia, and shared the positive results of those trials in August.

This phase-three clinical trial will focus on evaluating the candidate’s safety, efficacy and ability to provoke an immune response. The trial is being conducted over the next four to six weeks in the United Kingdom in partnership with the British government’s Vaccines Taskforce.

READ FULL ARTICLE HERE